EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators

Tara Graff iD, Ian Flinn, Jeff P Sharman iD, Steven Liu, Bertrand M Anz, Mitul Gandhi, Ayed Ayed iD, Richard Zuniga, Abdul Hai Mansoor, Lourenia M Cassoli, Mei Wu, Prachi Jani und 3 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Tara Graff und 14 weiteren Autor:innen. Beteiligte Einrichtung: Mission Cancer and Blood, Des Moines, Iowa, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Lymphoma, Follicular. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genentech Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preliminary data from the MorningSun study have demonstrated that outpatient subcutaneous mosunetuzumab can be safely administered.

Aims

This publication describes how community centers in the MorningSun phase 2 study of outpatient subcutaneous mosunetuzumab in B‐cell non‐Hodgkin lymphomas prepared workflow and logistics (staff coordination, practice networks, and patient support) to monitor patients for cytokine release syndrome (CRS) and other toxicities. Materials and Methods Ten investigators at US community practice study sites (one rural, seven urban, and two rural/urban) were interviewed between January 12 and February 22, 2024. Interview transcripts were analyzed qualitatively to identify key themes.

Results

Prior to the study, 7/10 had limited/no experience administering bispecific antibodies for lymphoma. Regarding preparation before treatment, staff education was the most frequent need (7/10). All sites provided in‐service training for staff involved with treatment administration. Most respondents (6/10) had multidisciplinary plans and agreed these eased logistical concerns. Out of hours, patients either called the triage team, a dedicated on‐call number, the physician, or the emergency department. Most practices had preexisting relationships with hospitals for CRS management. All practices established methods for outpatient CRS monitoring; patient education and caregivers played important roles, and all respondents encouraged patients to use self‐monitoring devices. Each community practice had different workflow and logistics based on their setting and infrastructure.

Conclusion

Community practices can leverage other sites' experiences and adopt an individualized approach to implementing bispecific antibodies safely and efficiently. Designating a physician champion could provide a local resource to address staff questions and concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalLymphoma, FollicularResearch PersonnelFemaleHumansClinical Trials, Phase II as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

best practicebispecific antibodiescare coordinationcommunity practiceoutpatient therapy

Substanzen

Antibodies, BispecificAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Mission Cancer and Blood, Des Moines, Iowa, USA.
  • Tennessee Oncology/OneOncology, Nashville, Tennessee, USA.
  • Willamette Valley Cancer Institute, Eugene, Oregon, USA.
  • Alaska Oncology & Hematology LLC, Anchorage, Alabama, USA.
  • Tennessee Oncology/OneOncology, Chattanooga, Tennessee, USA.
  • Virginia Cancer Specialists, Gainesville, Virginia, USA.

ORCID-Profile: Tara Graff, Jeff P Sharman, Ayed Ayed

Förderung

  • Genentech Inc

Zitieren

APA

Graff, T., Flinn, I., Sharman, J. P., Liu, S., Anz, B. M., Gandhi, M., Ayed, A., Zuniga, R., Mansoor, A. H., Cassoli, L. M., Wu, M., Jani, P., Biondo, J. M. L., Lin, T., & Burke, J. M. (2025). Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators. Cancer Medicine. https://doi.org/10.1002/cam4.70936

Vancouver

Graff T, Flinn I, Sharman JP, Liu S, Anz BM, Gandhi M, et al. Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators. Cancer Medicine. 2025. doi:10.1002/cam4.70936

BibTeX
@article{Graff2025,
  author = {Graff, Tara and Flinn, Ian and Sharman, Jeff P and Liu, Steven and Anz, Bertrand M and Gandhi, Mitul and Ayed, Ayed and Zuniga, Richard and Mansoor, Abdul Hai and Cassoli, Lourenia M and Wu, Mei and Jani, Prachi and Biondo, Juliana M L and Lin, Tony and Burke, John M},
  title = {Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70936}
}
Kostenlos starten →